<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/9C10D78F-6430-4CA7-9528-B96B0762A4C6"><gtr:id>9C10D78F-6430-4CA7-9528-B96B0762A4C6</gtr:id><gtr:name>Cardiff University</gtr:name><gtr:department>UNLISTED</gtr:department><gtr:address><gtr:line1>Research &amp; Consultancy</gtr:line1><gtr:line2>PO Box 923</gtr:line2><gtr:line4>Cardiff</gtr:line4><gtr:line5>South Glamorgan</gtr:line5><gtr:postCode>CF10 3TE</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9C10D78F-6430-4CA7-9528-B96B0762A4C6"><gtr:id>9C10D78F-6430-4CA7-9528-B96B0762A4C6</gtr:id><gtr:name>Cardiff University</gtr:name><gtr:address><gtr:line1>Research &amp; Consultancy</gtr:line1><gtr:line2>PO Box 923</gtr:line2><gtr:line4>Cardiff</gtr:line4><gtr:line5>South Glamorgan</gtr:line5><gtr:postCode>CF10 3TE</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/798CB33D-C79E-4578-83F2-72606407192C"><gtr:id>798CB33D-C79E-4578-83F2-72606407192C</gtr:id><gtr:name>EPSRC</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:line4>Swindon</gtr:line4><gtr:line5>Wiltshire</gtr:line5><gtr:postCode>SN2 1ET</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>CO_FUNDER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/3D9B6C4A-63ED-4A5C-9767-0F868A64CA6D"><gtr:id>3D9B6C4A-63ED-4A5C-9767-0F868A64CA6D</gtr:id><gtr:firstName>Terence</gtr:firstName><gtr:surname>Davis</gtr:surname><gtr:roles><gtr:role><gtr:name>RESEARCHER_COI</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/D09AE664-41EE-4980-B9DB-36942A07FC83"><gtr:id>D09AE664-41EE-4980-B9DB-36942A07FC83</gtr:id><gtr:firstName>Mark Christopher</gtr:firstName><gtr:surname>Bagley</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/C9E84E69-2A45-4348-9C8B-19FB6204B740"><gtr:id>C9E84E69-2A45-4348-9C8B-19FB6204B740</gtr:id><gtr:firstName>David</gtr:firstName><gtr:surname>Kipling</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=BB%2FD524140%2F1"><gtr:id>F64B2565-DF85-46BB-9FCE-0544F6EAA3E4</gtr:id><gtr:title>Dissecting the cause of premature replicative senescence of Werner syndrome cells using selective chemical inhibitors</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>BB/D524140/1</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:technicalSummary>Replicative senescence, the finite proliferative capacity of normal human cells in culture, could potentially contribute to the ageing of division-competent tissues. A powerful model system to study this is the genetic disease Werner&amp;iquest;s syndrome (WS). WS individuals age approximately 4-5 times faster than normal, but this dramatic premature ageing is largely restricted to division-competent tissues. Cultured WS fibroblasts undergo fewer population doublings (PDs) than their wild-type equivalents, providing a plausible explanation for the premature ageing phenotype of WS individuals. Both normal and WS fibroblasts use the progressive erosion of chromosomal telomeres as a cell division `counter&amp;iquest;, as shown by their immortalisation following forced expression of telomerase. However, our recent high-resolution analysis has argued against accelerated telomere erosion per cell division being responsible for their premature senescence. Rather, our data are consistent with an additional, telomere-independent mechanism operating in WS, one that synergises with telomere-driven senescence (TDS). Our recent work has provided a major clue as to its identity. Treatment of cultured WS cells with SB203580, an inhibitor of p38MAPK, essentially prevents all their premature ageing phenotypes. SB203580-treated WS cultures show a normal, `youthful&amp;iquest; morphology, their growth rate reverts to wild-type rates, and their cellular lifespan (number of PD achieved) is extended to be within the range observed for normal fibroblasts. In contrast, the senescence of normal human fibroblasts is largely unaffected by SB203580. We speculate that the absence of the WRNp recQ helicase, which has been shown to cause stalled replication forks, results in a `replication stress&amp;iquest; signal that is transduced by p38MAPK and synergises with TDS. Because this is a response to a fundamental defect in DNA replication, it is likely that a similar stress will also occur in vivo, in the proliferative tissues in WS induals. Here we will use the power of chemical genetics to create compound libraries based on known p38 inhibitors that have different binding kinetics in order to probe and dissect the stress related signaling pathways involving p38. We will address the extent to which p38MAPK, as opposed to other proteins, is the relevant target of SB203480 in this system, and whether this pathway synergises with TDS via one of two potential common pathway components (p53 and p21Waf1). The major methods used will be: heterocyclic chemical syntheses, the culture of primary and immortalised WS fibroblasts, immunocytochemistry/Western blotting, and specific kinase assays. These will be used to design specific inhibitors and to monitor their effects on both the WS in vitro phenotype and to address specific questions (e.g. p53, HSP27 phosphorylation). The results from this study will assess the ability of a range of p38 inhibitors, with very different modes of binding, substrate selectivity and inhibitory potencies, to prevent premature cell ageing of WS fibroblasts in vitro. These experiments will test our hypothesis that stress signal transduction in WS cells is responsible for the accelerated replicative decline and is transduced by the stress-activated mitogen kinase p38alpha. The goal of this programme is to use chemical inhibitors to intervene in the rapid ageing of WS cells and in so doing understand the biological system that causes cell senescence and morphology changes. The outcome of this proposal will add to this knowledge and, it is hoped, will provide valuable new insights into WS, the ageing process as a whole and the influence of p38alpha stress signaling on the fundamental mechanisms of ageing.</gtr:technicalSummary><gtr:fund><gtr:end>2009-06-26</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name></gtr:funder><gtr:start>2006-02-27</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>420603</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>258764</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>A combined genetic and small molecule approach to studying the role of the p38/MK2 stress signalling pathway in a human premature ageing syndrome.</gtr:description><gtr:end>2012-12-02</gtr:end><gtr:fundingOrg>Economic and Social Research Council</gtr:fundingOrg><gtr:fundingRef>RES-356-25-0024, ES/G037205/1</gtr:fundingRef><gtr:id>4AFFA7F6-A5BE-4F5D-9FFE-F9BC8C59F5FD</gtr:id><gtr:outcomeId>r-8129897683.97984806a80480</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2009-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>350351</gtr:amountPounds><gtr:country>France, French Republic</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Reconstruction of human skin equivalents using reticular fibroblasts, papillary fibroblasts and WS cells, and its modulation using p38 inhibitors.</gtr:description><gtr:end>2013-10-02</gtr:end><gtr:fundingOrg>L'Oreal (Paris)</gtr:fundingOrg><gtr:id>A7D2BEA3-CECC-4A56-9BEE-40B96288673E</gtr:id><gtr:outcomeId>5ebe17a45ebe17b8</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2009-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>258764</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>A combined genetic and small molecule approach to studying the role of the p38/MK2 stress signalling pathway in a human premature ageing syndrome.</gtr:description><gtr:end>2012-12-02</gtr:end><gtr:fundingOrg>Economic and Social Research Council</gtr:fundingOrg><gtr:fundingRef>RES-356-25-0024, ES/G037205/1</gtr:fundingRef><gtr:id>3BE2E9DF-4417-4CD4-9363-F90286D20991</gtr:id><gtr:outcomeId>5ed458665ed4587a</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2009-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>350351</gtr:amountPounds><gtr:country>France, French Republic</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Reconstruction of human skin equivalents using reticular fibroblasts, papillary fibroblasts and WS cells, and its modulation using p38 inhibitors.</gtr:description><gtr:end>2013-10-02</gtr:end><gtr:fundingOrg>L'Oreal (Paris)</gtr:fundingOrg><gtr:id>831BE461-15B3-4171-96E3-2479B48F1CBB</gtr:id><gtr:outcomeId>r-5248732459.963050687f80c</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2009-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>8AFCFCD0-CBC6-4E23-ABA6-54EB3284ECBC</gtr:id><gtr:title>Regiocontrolled synthesis of 3- and 5-aminopyrazoles, pyrazolo[3,4-d]pyrimidines, pyrazolo[3,4-b]pyridines and pyrazolo[3,4-b]quinolinones as MAPK inhibitors</gtr:title><gtr:parentPublicationTitle>Tetrahedron</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/14e8090fe82ea95cf1df6bf07d2bba1a"><gtr:id>14e8090fe82ea95cf1df6bf07d2bba1a</gtr:id><gtr:otherNames>Bagley M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>doi_55f94a94a6da5b6e</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CAD6581E-5A98-4B6F-A0E8-9030C00D2FED</gtr:id><gtr:title>Activation of p38 MAP kinase and stress signalling in fibroblasts from the progeroid Rothmund-Thomson syndrome.</gtr:title><gtr:parentPublicationTitle>Age (Dordrecht, Netherlands)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e652d93fb2ebe4adce6078cb4fe2f70c"><gtr:id>e652d93fb2ebe4adce6078cb4fe2f70c</gtr:id><gtr:otherNames>Davis T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0161-9152</gtr:issn><gtr:outcomeId>pm_5435aab5aab915fb6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9D0AC155-1C18-4EE1-9551-63B25B5082E2</gtr:id><gtr:title>Synthesis of the highly selective p38 MAPK inhibitor UR-13756 for possible therapeutic use in Werner syndrome.</gtr:title><gtr:parentPublicationTitle>Future medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3b56f28666e97438b7e93beed50afe57"><gtr:id>3b56f28666e97438b7e93beed50afe57</gtr:id><gtr:otherNames>Bagley MC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1756-8919</gtr:issn><gtr:outcomeId>pm_5435aab5aabfddf20</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BE4396EE-9316-4B23-AFCB-07D9057DDA9A</gtr:id><gtr:title>Synthesis and in vivo activity of MK2 and MK2 substrate-selective p38alpha(MAPK) inhibitors in Werner syndrome cells.</gtr:title><gtr:parentPublicationTitle>Bioorganic &amp; medicinal chemistry letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e652d93fb2ebe4adce6078cb4fe2f70c"><gtr:id>e652d93fb2ebe4adce6078cb4fe2f70c</gtr:id><gtr:otherNames>Davis T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0960-894X</gtr:issn><gtr:outcomeId>pm_5435aab5aabf38e7b</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7390C4FA-7689-40E0-A9E6-6A7AD6B1BDC4</gtr:id><gtr:title>Unlocking the chemotherapeutic potential of beta-aminovinyl ketones and related compounds.</gtr:title><gtr:parentPublicationTitle>ChemMedChem</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e21acd3732254e1e577252c792b8e233"><gtr:id>e21acd3732254e1e577252c792b8e233</gtr:id><gtr:otherNames>Gaber HM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1860-7179</gtr:issn><gtr:outcomeId>pm_5435aac5aac11a873</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FADC6F4B-1AEF-4D41-A42B-24B6FC66100A</gtr:id><gtr:title>Evaluating the role of p38 MAP kinase in growth of Werner syndrome fibroblasts.</gtr:title><gtr:parentPublicationTitle>Annals of the New York Academy of Sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e652d93fb2ebe4adce6078cb4fe2f70c"><gtr:id>e652d93fb2ebe4adce6078cb4fe2f70c</gtr:id><gtr:otherNames>Davis T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0077-8923</gtr:issn><gtr:outcomeId>pm_5435aab5aaba5d8da</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2855BEE6-A265-41E3-82EE-C0181BE46C50</gtr:id><gtr:title>Microwave-assisted synthesis of N-pyrazole ureas and the p38? inhibitor BIRB 796 for study into accelerated cell ageing</gtr:title><gtr:parentPublicationTitle>Organic &amp; Biomolecular Chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/14e8090fe82ea95cf1df6bf07d2bba1a"><gtr:id>14e8090fe82ea95cf1df6bf07d2bba1a</gtr:id><gtr:otherNames>Bagley M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:outcomeId>doi_53d029029c9bbb8c</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A9349992-9677-4B3F-8388-6902B18B183F</gtr:id><gtr:title>The role of cellular senescence in Werner syndrome: toward therapeutic intervention in human premature aging.</gtr:title><gtr:parentPublicationTitle>Annals of the New York Academy of Sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e652d93fb2ebe4adce6078cb4fe2f70c"><gtr:id>e652d93fb2ebe4adce6078cb4fe2f70c</gtr:id><gtr:otherNames>Davis T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0077-8923</gtr:issn><gtr:outcomeId>pm_5435aac5aac07c361</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D7DEB8A5-2CB7-4622-BE66-E1EC1F1821AA</gtr:id><gtr:title>Microwave-Assisted Synthesis of a MK2 Inhibitor by Suzuki-Miyaura Coupling for Study in Werner Syndrome Cells.</gtr:title><gtr:parentPublicationTitle>Pharmaceuticals (Basel, Switzerland)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3b56f28666e97438b7e93beed50afe57"><gtr:id>3b56f28666e97438b7e93beed50afe57</gtr:id><gtr:otherNames>Bagley MC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1424-8247</gtr:issn><gtr:outcomeId>585d4125caa7f4.24367340</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D06D4686-876E-4C85-AD6A-70F15717428B</gtr:id><gtr:title>p38 (MAPK) stress signalling in replicative senescence in fibroblasts from progeroid and genomic instability syndromes.</gtr:title><gtr:parentPublicationTitle>Biogerontology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4d7ee22bdd3e477b3f90b723e16046fd"><gtr:id>4d7ee22bdd3e477b3f90b723e16046fd</gtr:id><gtr:otherNames>Tivey HS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1389-5729</gtr:issn><gtr:outcomeId>pm_5435aab5aabdc50cc</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>02B4A632-EB19-4134-8A63-EE8092A4EEC7</gtr:id><gtr:title>Microwave-assisted Ullmann C-S bond formation: synthesis of the P38alpha MAPK clinical candidate VX-745.</gtr:title><gtr:parentPublicationTitle>The Journal of organic chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3b56f28666e97438b7e93beed50afe57"><gtr:id>3b56f28666e97438b7e93beed50afe57</gtr:id><gtr:otherNames>Bagley MC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-3263</gtr:issn><gtr:outcomeId>pm_5435aab5aabcf0dce</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B7C55099-5C0C-449C-B98C-6BCC8EED808D</gtr:id><gtr:title>Rapid synthesis of VX-745: p38 MAP kinase inhibition in Werner syndrome cells.</gtr:title><gtr:parentPublicationTitle>Bioorganic &amp; medicinal chemistry letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3b56f28666e97438b7e93beed50afe57"><gtr:id>3b56f28666e97438b7e93beed50afe57</gtr:id><gtr:otherNames>Bagley MC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0960-894X</gtr:issn><gtr:outcomeId>pm_5435aab5aabe7b765</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CD26585B-2DA2-4AB1-9CEC-0D2C4CCEC418</gtr:id><gtr:title>Microwave-assisted synthesis of 5-aminopyrazol-4-yl ketones and the p38(MAPK) inhibitor RO3201195 for study in Werner syndrome cells.</gtr:title><gtr:parentPublicationTitle>Bioorganic &amp; medicinal chemistry letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3b56f28666e97438b7e93beed50afe57"><gtr:id>3b56f28666e97438b7e93beed50afe57</gtr:id><gtr:otherNames>Bagley MC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0960-894X</gtr:issn><gtr:outcomeId>pm_5435aab5aabbbafa7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>340102F0-7CCB-4370-ADCE-6001EDBAAF07</gtr:id><gtr:title>Microwave-assisted synthesis of a pyrazolyl ketone library for evaluation as p38 MAPK inhibitors in Werner syndrome cells.</gtr:title><gtr:parentPublicationTitle>Future medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3b56f28666e97438b7e93beed50afe57"><gtr:id>3b56f28666e97438b7e93beed50afe57</gtr:id><gtr:otherNames>Bagley MC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1756-8919</gtr:issn><gtr:outcomeId>pm_5435aab5aabc5d701</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>37E283CB-EC37-4EBD-9487-AD14F6FA8FE0</gtr:id><gtr:title>The effect of RO3201195 and a pyrazolyl ketone P38 MAPK inhibitor library on the proliferation of Werner syndrome cells.</gtr:title><gtr:parentPublicationTitle>Organic &amp; biomolecular chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3b56f28666e97438b7e93beed50afe57"><gtr:id>3b56f28666e97438b7e93beed50afe57</gtr:id><gtr:otherNames>Bagley MC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1477-0520</gtr:issn><gtr:outcomeId>585d7386141aa3.86005456</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0A36C05E-AED7-4513-853C-378520D170E6</gtr:id><gtr:title>Assessing the role of stress signalling via p38 MAP kinase in the premature senescence of ataxia telangiectasia and Werner syndrome fibroblasts.</gtr:title><gtr:parentPublicationTitle>Biogerontology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e652d93fb2ebe4adce6078cb4fe2f70c"><gtr:id>e652d93fb2ebe4adce6078cb4fe2f70c</gtr:id><gtr:otherNames>Davis T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1389-5729</gtr:issn><gtr:outcomeId>pm_5435aab5aab9c19c0</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>87797C01-EF52-4C73-B461-15DC62DF5A5C</gtr:id><gtr:title>Gram-scale synthesis of the p38a MAPK-inhibitor VX-745 for preclinical studies into Werner syndrome.</gtr:title><gtr:parentPublicationTitle>Future medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3b56f28666e97438b7e93beed50afe57"><gtr:id>3b56f28666e97438b7e93beed50afe57</gtr:id><gtr:otherNames>Bagley MC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1756-8919</gtr:issn><gtr:outcomeId>pm_5435aab5aabb0655b</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">BB/D524140/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>